ATE417067T1 - Rs7 antikörper - Google Patents

Rs7 antikörper

Info

Publication number
ATE417067T1
ATE417067T1 AT03743420T AT03743420T ATE417067T1 AT E417067 T1 ATE417067 T1 AT E417067T1 AT 03743420 T AT03743420 T AT 03743420T AT 03743420 T AT03743420 T AT 03743420T AT E417067 T1 ATE417067 T1 AT E417067T1
Authority
AT
Austria
Prior art keywords
amino acid
sequences
murine
cdr2
cdr3
Prior art date
Application number
AT03743420T
Other languages
English (en)
Inventor
Serengulam Govindan
Zhengxing Qu
Hans Hansen
David Goldenberg
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE417067T1 publication Critical patent/ATE417067T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03743420T 2002-03-01 2003-03-03 Rs7 antikörper ATE417067T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36022902P 2002-03-01 2002-03-01

Publications (1)

Publication Number Publication Date
ATE417067T1 true ATE417067T1 (de) 2008-12-15

Family

ID=27788969

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743420T ATE417067T1 (de) 2002-03-01 2003-03-03 Rs7 antikörper

Country Status (18)

Country Link
US (10) US7238785B2 (de)
EP (3) EP3483183B1 (de)
JP (1) JP4354280B2 (de)
KR (1) KR101002443B1 (de)
CN (2) CN100360567C (de)
AT (1) ATE417067T1 (de)
AU (1) AU2003209447B8 (de)
CA (1) CA2478047C (de)
CY (1) CY1124289T1 (de)
DE (1) DE60325184D1 (de)
DK (1) DK3483183T3 (de)
ES (1) ES2871905T3 (de)
HU (1) HUE054986T2 (de)
IL (1) IL163852A0 (de)
PT (1) PT3483183T (de)
SI (1) SI3483183T1 (de)
TR (1) TR201901824T4 (de)
WO (1) WO2003074566A2 (de)

Families Citing this family (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) * 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
WO2004051214A2 (en) * 2002-06-05 2004-06-17 Pharmacia & Upjohn Company Use of fluorine nmr for high throughput screening
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
EP1572131B1 (de) 2002-10-08 2016-07-06 Immunomedics, Inc. Antikörper-therapie
JP4959136B2 (ja) 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド 細胞内で開裂可能な結合を有する免疫接合体
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
US10376711B2 (en) 2003-03-14 2019-08-13 Light Sciences Oncology Inc. Light generating guide wire for intravascular use
CN2885311Y (zh) 2006-01-18 2007-04-04 郑成福 经尿道光动力疗法前列腺治疗仪
EP1638510B1 (de) * 2003-07-01 2015-09-02 Immunomedics, Inc. Multivalente träger von bispezifischen antikörpern
WO2005027808A1 (en) 2003-09-12 2005-03-31 Z-Medica Corporation Calcium zeolite hemostatic agent
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
MXPA06004199A (es) * 2003-10-17 2006-06-28 Novo Nordisk As Terapia en combinacion.
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
AU2005214361B2 (en) * 2004-02-13 2011-03-24 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
JP2008531498A (ja) 2005-02-15 2008-08-14 バージニア コモンウェルス ユニバーシティ 緊急止血ならびに急性創傷および慢性潰瘍の治療のための鉱物技術（ｍｔ）
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US9326995B2 (en) 2005-04-04 2016-05-03 The Regents Of The University Of California Oxides for wound healing and body repair
GB2429013C (en) * 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
WO2007085814A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420041B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US8938898B2 (en) 2006-04-27 2015-01-27 Z-Medica, Llc Devices for the identification of medical products
US7604819B2 (en) 2006-05-26 2009-10-20 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
WO2010042562A2 (en) 2008-10-06 2010-04-15 Minerva Biotechnologies Corporation Muc1* antibodies
EP2386062B1 (de) * 2009-01-09 2016-01-06 Oxford Biomedica (UK) Ltd Faktoren
CA2750038C (en) 2009-02-05 2016-10-04 Oncoxx S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
EP3243527B1 (de) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunkonjugate mit einem intrazellulär spaltbaren linker
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
US9296785B2 (en) 2009-04-17 2016-03-29 Wake Forest University Health Sciences IL-13 receptor binding peptides
WO2011008912A1 (en) * 2009-07-16 2011-01-20 Beckman Coulter, Inc. Novel fluorescent dyes and uses thereof
CN102596235A (zh) * 2009-08-31 2012-07-18 免疫医疗公司 显示有效细胞毒活性的包含豹蛙酶(rap)的免疫毒素的组合物和使用方法
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2506881B1 (de) * 2009-12-02 2024-03-06 Immunomedics, Inc. Kombination aus radioimmuntherapie und antikörper-arznei-konjugaten für verbesserte krebstherapie
WO2011085289A1 (en) * 2010-01-11 2011-07-14 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Production of a monoclonal antibody therapeutic against west nile virus in plants
US8362207B2 (en) 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
SG10201503904XA (en) * 2010-05-17 2015-06-29 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
JPWO2011155579A1 (ja) * 2010-06-10 2013-08-15 北海道公立大学法人 札幌医科大学 抗Ｔｒｏｐ−２抗体
NZ607472A (en) * 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
US8858969B2 (en) 2010-09-22 2014-10-14 Z-Medica, Llc Hemostatic compositions, devices, and methods
BR112013024521A2 (pt) * 2011-03-25 2019-09-24 Genentech Inc métodos de purificação de proteínas
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9499608B2 (en) 2011-06-08 2016-11-22 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
WO2012167346A1 (en) 2011-06-10 2012-12-13 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Anti-ricin antibodies and uses thereof
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
US9427464B2 (en) * 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
WO2013191836A1 (en) 2012-06-22 2013-12-27 Z-Medica, Llc Hemostatic devices
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
PL3321254T3 (pl) * 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
WO2014057687A1 (ja) 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
AU2013360335B2 (en) * 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
JP2016513098A (ja) 2013-02-07 2016-05-12 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
EP2774930A1 (de) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocenverbindungen und markierte Moleküle damit für In-vivo-Bildgebung
PL2970492T3 (pl) 2013-03-15 2019-10-31 Univ Wake Forest Health Sciences Przeciwciała przeciwko ludzkim i psim il-13ra2
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CA2920192A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
EP3456700A1 (de) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Markierte inhibitoren des prostataspezifischen membranantigens (psma), deren verwendung als kontrastmittel und pharmazeutika zur behandlung von prostatakrebs
US9975942B2 (en) 2013-11-11 2018-05-22 Wake Forest University Health Services EPHA3 And multi-valent targeting of tumors
PT3088419T (pt) 2013-12-25 2019-01-11 Daiichi Sankyo Co Ltd Conjugado de anticorpo anti-trop2-fármaco
WO2015113055A2 (en) 2014-01-27 2015-07-30 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ade) of infection
JP6447933B2 (ja) * 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
CN104974263A (zh) * 2014-04-09 2015-10-14 广州复能基因有限公司 一种人重组乙型干扰素融合蛋白
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
WO2016037985A1 (en) 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
CN107406508B (zh) * 2014-12-04 2022-04-05 地中海治疗诊断有限公司 人源化的抗trop-2单克隆抗体及其应用
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
EP3611506B1 (de) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Vorhersage der therapeutischen reaktion auf alvocidib durch mitochondriales profilieren
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
PL3298021T3 (pl) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Proleki alvocidibu o zwiększonej biodostępności
EP3307282A4 (de) * 2015-06-12 2019-05-01 Immunomedics, Inc. Krankheitstherapie mit konstrukten von chimärem antigen-rezeptor (car) und t-zellen- (car-t) oder nk-zellen (car-nk)-exprimierenden car-konstrukten
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
WO2017024073A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
JP6983661B2 (ja) * 2015-12-24 2021-12-17 協和キリン株式会社 α、β不飽和アミド化合物
WO2017139623A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
EP3448260A4 (de) 2016-04-27 2019-10-09 Immunomedics, Inc. Wirksamkeit von anti-trop-2-sn-38-antikörper-wirkstoff-konjugaten zur therapie von rezidivierten/refraktären tumoren gegen checkpoint-inhibitoren
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN108697809A (zh) * 2016-08-23 2018-10-23 四川科伦博泰生物医药股份有限公司 一种抗体-药物偶联物及其制备方法和应用
JP6786973B2 (ja) * 2016-09-08 2020-11-18 ブラザー工業株式会社 画像解析装置
US11498977B2 (en) 2016-09-29 2022-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP3552626A4 (de) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited Kombination aus antikörper-wirkstoff-konjugat und immun-checkpoint-inhibitor
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
EP3572428A4 (de) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited Anti-gpr20-antikörper und anti-gpr20-antikörper-arzneimittel-konjugat
KR20190123299A (ko) * 2017-02-27 2019-10-31 드래곤플라이 쎄라퓨틱스, 인크. Caix, ano1, 메소텔린, trop2, cea, 또는 클라우딘-18.2를 표적화하는 다중특이적 결합 단백질
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
CN110312730B (zh) 2017-04-19 2024-06-18 四川科伦博泰生物医药股份有限公司 细胞毒素和偶联物、其用途和制备方法
CN107446050A (zh) * 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
KR20250084239A (ko) 2017-08-31 2025-06-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
SG11202001430SA (en) 2017-09-29 2020-04-29 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
CN119241554A (zh) 2017-12-15 2025-01-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN108680750A (zh) * 2017-12-29 2018-10-19 广西壮族自治区人民医院 Trop2蛋白表达量的elisa检测方法及试剂盒
WO2019148186A1 (en) * 2018-01-29 2019-08-01 Silarus Therapeutics, Inc. Antibodies binding erfe and methods of use
HRP20240756T1 (hr) 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1-eksatekan antitijelo-lijek konjugat
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
EP3831412A4 (de) 2018-07-31 2022-04-27 Daiichi Sankyo Company, Limited Behandlung von metastatischem gehirntumor durch verabreichung eines antikörper-arzneimittel-konjugats
EP3842546A4 (de) 2018-08-23 2022-06-29 Daiichi Sankyo Company, Limited Sensitivitätsmarker für antikörperarzneimittelkonjugate
US12594345B2 (en) 2018-09-26 2026-04-07 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
WO2020094670A1 (en) 2018-11-05 2020-05-14 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
JP2022511029A (ja) 2018-12-04 2022-01-28 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
US20220089768A1 (en) * 2019-01-04 2022-03-24 Trio Pharmaceuticals, Inc. Multi-specific protein molecules and uses thereof
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
BR112021017350A2 (pt) 2019-03-27 2021-11-16 Daiichi Sankyo Co Ltd Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
IL288485B2 (en) 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
CN114845710A (zh) 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
WO2021136475A1 (en) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. A drug conjugate and applications thereof
WO2021148003A1 (zh) 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
TWI891714B (zh) * 2020-01-22 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 抗trop-2抗體-依喜替康類似物偶聯物及其醫藥用途
CN115398010A (zh) 2020-03-20 2022-11-25 免疫医疗公司 用于戈沙妥珠单抗疗法的生物标志物
TW202200212A (zh) 2020-05-03 2022-01-01 中國大陸商聯寧（蘇州）生物製藥有限公司 包含抗-trop-2抗體之抗體藥物結合物
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CA3188014A1 (en) * 2020-06-22 2021-12-30 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Anti-trop2 antibody
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
CN115803010A (zh) 2020-07-09 2023-03-14 豪夫迈·罗氏有限公司 浓缩的蛋白质组合物、它们的制备及其用途
AU2021309966A1 (en) 2020-07-15 2023-02-09 Biogen Ma Inc. Medical system including two access ports
CN116234586A (zh) 2020-08-13 2023-06-06 博尔特生物治疗药物有限公司 吡唑并氮呯免疫缀合物及其用途
WO2022046658A1 (en) * 2020-08-24 2022-03-03 Janux Therapeutics, Inc. Antibodies targeting trop2 and cd3 and uses thereof
KR20230086712A (ko) * 2020-10-14 2023-06-15 상하이 한서 바이오메디컬 컴퍼니 리미티드 항-trop-2 항체, 이의 항원-결합 단편 또는 이의 돌연변이체, 및 이의 의학적 용도
CN116916940A (zh) * 2020-11-04 2023-10-20 美洛德生物医药公司 工程化嵌合融合蛋白组合物及其使用方法
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
IT202000031838A1 (it) 2020-12-22 2022-06-22 Saverio Alberti Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici
CN114685669A (zh) * 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
KR20230147092A (ko) * 2021-01-22 2023-10-20 바이원큐어 테라퓨틱스, 인크. 항-her-2/trop-2 작제물 및 이의 용도
AU2021423664B2 (en) 2021-01-28 2026-02-05 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
TW202304520A (zh) 2021-03-26 2023-02-01 美商博特生物治療公司 ２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途
CN117940168A (zh) 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
CN117337195A (zh) 2021-04-29 2024-01-02 上海汇连生物医药有限公司 抗体偶联药物的制备方法及应用
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN115429893A (zh) 2021-06-02 2022-12-06 百奥泰生物制药股份有限公司 药物偶联物及其用途
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
US12227574B2 (en) 2021-06-17 2025-02-18 Amberstone Biosciences, Inc. Anti-CD3 constructs and uses thereof
CA3224887A1 (en) * 2021-07-09 2023-01-12 Board Of Regents, The University Of Texas System Chimeric antigen receptor to target trop-2-positive cancers
MX2024000895A (es) 2021-07-21 2024-02-06 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene el conjugado del farmaco anticuerpo anti-trop2 y su aplicacion.
CA3228311A1 (en) 2021-08-12 2023-02-16 Ke HE Bispecific recombinant protein and use thereof
CN118043080A (zh) 2021-08-13 2024-05-14 昆山新蕴达生物科技有限公司 一种基于微管抑制剂的抗体偶联药物
CN117881431A (zh) 2021-08-24 2024-04-12 昆山新蕴达生物科技有限公司 一种由可断裂连接子偶联的抗体偶联药物
EP4408468A4 (de) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc Mehrere formate molekularer komplexe
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954B2 (en) 2021-10-29 2026-04-23 Gilead Sciences, Inc. Cd73 compounds
CN118475372A (zh) 2021-10-29 2024-08-09 博尔特生物治疗药物有限公司 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途
CN116199784A (zh) * 2021-11-30 2023-06-02 泽达生物医药有限公司 抗trop-2/pd-l1双特异性抗体
KR20240113514A (ko) 2021-11-30 2024-07-22 다이이찌 산쿄 가부시키가이샤 프로테아제 분해성 마스크 항체
WO2023103854A1 (zh) 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
AU2022419982B2 (en) 2021-12-22 2026-04-16 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118401259A (zh) 2022-01-13 2024-07-26 四川科伦博泰生物医药股份有限公司 抗trop-2抗体偶联药物和其他治疗剂的组合用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
KR20240141757A (ko) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 환경 응답성 마스킹 항체 및 그 이용
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode
WO2023155808A1 (zh) 2022-02-16 2023-08-24 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
US20250154278A1 (en) * 2022-02-23 2025-05-15 Janux Therapeutics, Inc. Optimized antibodies targeting trop2 and uses thereof
US20240059786A1 (en) * 2022-02-24 2024-02-22 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
EP4493554A1 (de) 2022-03-17 2025-01-22 Gilead Sciences, Inc. Degrader der ikaros-zinkfingerfamilie und verwendungen davon
CN119212731A (zh) 2022-03-23 2024-12-27 新锐生物技术公司 用于靶向表达Trop-2的肿瘤的抗体缀合物
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
EP4508083A1 (de) 2022-04-13 2025-02-19 Gilead Sciences, Inc. Kombinationstherapie zur behandlung von tumorantigenexprimierenden krebsarten
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
WO2023215789A2 (en) * 2022-05-04 2023-11-09 Janux Therapeutics, Inc. Tumor activated antibodies targeting trop2 and uses thereof
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
EP4545099A1 (de) 2022-06-27 2025-04-30 Bio-Thera Solutions, Ltd. Verfahren zur behandlung von soliden tumoren
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
CN117801107A (zh) 2022-09-30 2024-04-02 上海迪诺医药科技有限公司 苯并氮杂卓衍生物、含其的偶联物及其应用
WO2024097812A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Therapy for treating bladder cancer
WO2024109949A1 (zh) 2022-11-25 2024-05-30 明慧医药（杭州）有限公司 一种抗肿瘤化合物及其应用
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
EP4637833A2 (de) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon-abbaukonjugate und verwendungen davon
EP4653017A1 (de) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antikörper-wirkstoff-konjugat und verwendung davon
CN120981252A (zh) 2023-02-14 2025-11-18 博尔特生物治疗药物有限公司 氮杂-苯并氮杂䓬免疫缀合物及其用途
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
EP4695295A1 (de) * 2023-04-14 2026-02-18 Xencor, Inc. Anti-cd28 x anti-trop2-antikörper
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AR132494A1 (es) 2023-04-24 2025-07-02 Merck Sharp & Dohme Llc Aglutinantes de trop2 y conjugados de estos
AU2024261962A1 (en) * 2023-04-24 2025-11-13 Merck Sharp & Dohme Llc Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250099605A1 (en) 2023-08-15 2025-03-27 Gilead Sciences, Inc. Treatment of non-small cell lung cancer using sacituzumab govitecan and an anti-pd-1 antibody or antigen binding fragment thereof
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025081075A1 (en) 2023-10-13 2025-04-17 Gilead Sciences, Inc. Combination therapies for treating cancers
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4552657A1 (de) 2023-11-07 2025-05-14 Bayer Aktiengesellschaft Radiopharmazeutische komplexe und kombinationen
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025149014A1 (en) 2024-01-12 2025-07-17 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition
TW202535951A (zh) * 2024-01-15 2025-09-16 大陸商石藥集團巨石生物製藥有限公司 結合ｔｒｏｐ２的抗體或抗體片段及包含其的藥物偶聯物
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025159982A1 (en) 2024-01-22 2025-07-31 Gilead Sciences, Inc. Treatment of non-small cell lung cancer using sacituzumab govitecan
WO2025212469A1 (en) * 2024-04-03 2025-10-09 Merck Sharp & Dohme Llc Use of an immunoconjugate for the treatment of gastric cancer
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025251025A1 (en) 2024-05-31 2025-12-04 Gilead Sciences, Inc. Sacituzumab govitecan formulations and methods of manufacture
WO2026019374A1 (en) 2024-07-19 2026-01-22 Hummingbird Bioscience Pte. Ltd. Trop2-binding molecules
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds
WO2026050351A1 (en) 2024-08-27 2026-03-05 The Johns Hopkins Univeristy Functionalized lipid nanoparticles for targeted delivery to endometrium
WO2026055185A1 (en) 2024-09-04 2026-03-12 Bolt Biotherapeutics, Inc. Sting agonist immunoconjugates and uses thereof
WO2026059500A1 (en) 2024-09-13 2026-03-19 Hummingbird Bioscience Pte. Ltd. Trop2-binding molecules
WO2026089992A1 (en) 2024-10-21 2026-04-30 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0672068A4 (de) 1992-09-25 1997-02-26 Commw Scient Ind Res Org Zielmoleküle-bindende polypeptide.
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
ATE265532T1 (de) 1995-10-19 2004-05-15 Bristol Myers Squibb Co Monoklonaler antikörper br110 und dessen anwendung
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
US6558669B1 (en) 1996-08-28 2003-05-06 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
AU770952B2 (en) * 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
JP2005514030A (ja) * 2001-12-26 2005-05-19 イミューノメディクス、インコーポレイテッド Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法
US9770517B2 (en) * 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20080305104A1 (en) 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2750038C (en) 2009-02-05 2016-10-04 Oncoxx S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
SG10201503904XA (en) 2010-05-17 2015-06-29 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
JPWO2011155579A1 (ja) 2010-06-10 2013-08-15 北海道公立大学法人 札幌医科大学 抗Ｔｒｏｐ−２抗体
SG10201605401WA (en) 2011-04-01 2016-08-30 Wyeth Llc Antibody-drug conjugates
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
KR102188537B1 (ko) 2019-08-14 2020-12-08 라인플러스 주식회사 유니캐스트 및 멀티캐스트를 이용한 그룹 통화 방법 및 시스템

Also Published As

Publication number Publication date
KR20040089694A (ko) 2004-10-21
CA2478047C (en) 2014-01-21
US9833511B2 (en) 2017-12-05
EP3483183A1 (de) 2019-05-15
JP2006502698A (ja) 2006-01-26
US20180133322A1 (en) 2018-05-17
US9849176B2 (en) 2017-12-26
HUE054986T2 (hu) 2021-10-28
CN101264325A (zh) 2008-09-17
US20140120035A1 (en) 2014-05-01
EP3483183B1 (de) 2021-04-21
US8574575B2 (en) 2013-11-05
US20120141372A1 (en) 2012-06-07
DK3483183T3 (da) 2021-06-21
EP2287201A2 (de) 2011-02-23
EP2287201B1 (de) 2018-12-12
US9999668B2 (en) 2018-06-19
US8084583B2 (en) 2011-12-27
US20070212350A1 (en) 2007-09-13
EP1483295A2 (de) 2004-12-08
KR101002443B1 (ko) 2010-12-17
US10179171B2 (en) 2019-01-15
SI3483183T1 (sl) 2021-08-31
PT3483183T (pt) 2021-06-02
TR201901824T4 (tr) 2019-03-21
US20180250406A1 (en) 2018-09-06
US20140286861A1 (en) 2014-09-25
ES2871905T3 (es) 2021-11-02
AU2003209447A1 (en) 2003-09-16
CN1649903A (zh) 2005-08-03
US20100221177A1 (en) 2010-09-02
AU2003209447B2 (en) 2008-09-18
CN100360567C (zh) 2008-01-09
CY1124289T1 (el) 2022-07-22
IL163852A0 (en) 2005-12-18
CA2478047A1 (en) 2003-09-12
US20190083621A1 (en) 2019-03-21
US7238785B2 (en) 2007-07-03
CN101264325B (zh) 2017-03-01
US7517964B2 (en) 2009-04-14
US8758752B2 (en) 2014-06-24
US20040001825A1 (en) 2004-01-01
JP4354280B2 (ja) 2009-10-28
WO2003074566A3 (en) 2004-03-04
EP2287201A3 (de) 2012-04-04
EP1483295B1 (de) 2008-12-10
DE60325184D1 (de) 2009-01-22
AU2003209447B8 (en) 2008-10-23
WO2003074566A2 (en) 2003-09-12
US20170274079A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
CY1124289T1 (el) Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
HRP20181069T1 (hr) Antagonistička protutijela na il-17
TW200716182A (en) Antibodies directed to CD20 and uses thereof
AR035581A1 (es) Anticuerpos para il-1beta humana
EP2796466A3 (de) Für IL-31 spezifische humanisierte Antikörpermoleküle
IL173323A0 (en) Antibodies directed to parathyroid hormone (pth) and uses thereof
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
ITRM20030601A1 (it) Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
NZ593068A (en) IL-18 antibody
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
GEP20074222B (en) Antibodies to cd40
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2004050683A3 (en) Antibodies directed to tumor necrosis factor and uses thereof
DE602005022928D1 (de) Antikörper gegen gpnmb und ihre verwendungen
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
BR0207151A (pt) Moléculas de aglutinação terapêuticas
WO2006039258A3 (en) Human antibodies against parathyroid hormone
WO2004050032A3 (en) Antibodies against drugs of abuse
ECSP066432A (es) Moléculas de enlace terapéuticas
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties